Companies/US/ABT

ABBOTT LABORATORIES

Income flow

Annual
ABT 10-K Income StatementPeriod 2025-12-31Source 10-K
Medical Devices$21BDiagnostic Products$9BNutritional Products$8BEstablished Pharmaceutical Products$6BRevenue$44B+6% Y/YGross profit$25B+8% Y/YCost of revenue$19BOperating profit$8B+18% Y/YOperating expenses$17BNet profit$7B-51% Y/YTax$2BSG&A$12BR&D & other$5B

As-filed revenue segments and annual P&L (gross, opex, tax, net). Layout inspired by SankeyArt finance diagrams.

Revenue mix

2025-12-31 · 10-K · USD
By activity
By activity$44.3B
  • Medical Devices$21.4B48.3%
  • Diagnostic Products$8.9B20.2%
  • Nutritional Products$8.5B19.1%
  • Established Pharmaceutical Products$5.5B12.5%
By geography
By geography$71.5B
  • Non-US$27.2B38.0%
  • United States$17.1B23.9%
  • All Other Countries$16.0B22.3%
  • DE$2.8B3.9%
  • CN$1.9B2.7%
  • CH$1.9B2.6%
  • IN$1.9B2.6%
  • JP$1.5B2.1%
  • GB$1.3B1.9%

Capital & dividends

YieldTrailing twelve-month dividends as a percent of the current share price (income yield).2.46%5y avgAverage dividend yield over the past five years — a smoother view than the latest print.1.85%Trailing DPSCash dividends paid per share over the last twelve months (dividend per share, trailing).2.48PayoutShare of earnings paid out as dividends. Higher means more income returned; lower leaves more for reinvestment.78.7%Shares outTotal shares currently outstanding (issued and not retired).1.74BFloatShares available to trade — outstanding minus closely held (insiders, strategic holders).1.72B
Upcoming dividend
Next ex-div
2026-10-15 · declared
Next pay
2026-11-16
Last cash
0.63 · 2026-07-15
Stock splits
  1. 10000:47982013-01-02

Valuation

Trailing PE 33.1 (2025-12-31)PE trend

Fiscal PE5

PeriodEPSClosePE
2025-12-313.7212333.1
2024-12-317.64108.9814.3
2023-12-313.26103.9831.9
2022-12-313.91101.6826.0
2021-12-313.94128.1932.5

PE = stored close ÷ as-filed diluted EPS (annual 10-K / 20-F). Not a vendor PE series.